Human skeletal myoblasts spontaneously activate allogeneic complement but are resistant to killing

Journal of Immunology

Volumn 156, Issue 9, 1996, Pages 3402-3411

  Gasque, Philippe ^a   Morgan, B Paul ^a   Legoedec, Jocelyne ^b   Chan, Philippe ^b   Fontaine, Marc ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CD59 ANTIGEN; CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT RECEPTOR; DECAY ACCELERATING FACTOR; GAMMA INTERFERON; MEMBRANE PROTEIN; OPSONIN; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN;

ARTICLE; CELL KILLING; COMPLEMENT ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; MYOBLAST; OPSONIZATION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SKELETAL MUSCLE; TUMOR CELL LINE;

CELL DEATH; CELLS, CULTURED; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT PATHWAY, CLASSICAL; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNITY, NATURAL; MUSCLE, SKELETAL; RECEPTORS, COMPLEMENT 3B; RECOMBINANT PROTEINS; RHABDOMYOSARCOMA; RNA, MESSENGER; SOLUBILITY; TUMOR CELLS, CULTURED;

EID: 0030004619     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Blau, H. M., and C. Webster. 1981. Isolation and characterization of human muscle cells. Proc. Natl. Acad. Sci. USA 78:5623.
2. Rando, T. A., and H. M. Blau. 1994. Primary mouse myoblast purification, characterization, and transplantation for cell mediated gene therapy. J. Cell Biol. 125:1275.
3. Watt, D. J., J. E. Morgan, and T. A. Partridge. 1984. Use of mononuclear precursor cells to insert allogeneic genes into growing mouse muscles. Muscle Nerve 7:741.
4. Partridge, T. A., M. Grounds, and J. C. Sloper. 1978. Evidence of fusion between host and donor myoblasts in skeletal muscle grafts. Nature 273:306.
5. Karpati, G., Y. Pouliot, G. E. Zubrzycka, S. Carpenter, P. N. Ray, R. G. Worton, and P. Holland. 1989. Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am. J. Pathol. 135:27.
6. Partridge, T. A., J. E. Morgan, G. R. Coulton, E. P. Hoffman, and L. M. Kunkel. 1989. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337:176.
7. Gussoni, E., G. K. Pavlath, A. M. Lanctot, K. R. Sharma, R. G. Miller, L. Steinman, and H. M. Blau. 1992. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356:435.
8. Barr, E., and J. M. Leiden. 1991. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254:1507.
9. Dhawan, J., L. C. Pan, G. K. Pavlath, A. M. Lanctot, K. R. Sharma, R. G. Miller, L. Seinman, and H. M. Blau. 1992. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254:1509.
10. Dai, Y., M. Roman, R. K. Naviaux, and I. M. Verma. 1992. Gene therapy via primary myoblasts: long term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA 89:10892.
11. Jiao, S., V. Gurevich, and J. A. Wolff. 1993. Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362:450.
12. Labrecque, C., R. Roy, and J. P. Tremblay. 1991. Immune reactions after myoblast transplantation in mouse muscles. Transplant. Proc. 24:2889.
13. Huard, J., R. Roy, J. P. Bouchard, F. Malouin, C. L. Richards, and J. P. Tremblay. 1992. Human myoblast transplantations between immunohistocompatible donors and receipients produce immune reactions. Transplant. Proc. 24:3049.
14. Tremblay, J. P., F. Malouin, R. Roy, J. Huard, J. P. Bouchard, A. Satoh, and C. L. Richards. 1993. Results of a triple blind clinical study of myoblast transplantations without immunosuppresive treatment in young boys with Duchenne muscular dystrophy. Cell Transplantation 2:99.
15. Hohlfeld, R., and A. G. Engel. 1990. Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells: relevance to myoblast transplantation. J. Clin. Invest. 86:370.
16. Engel, A. G., and G. Biesecker. 1982. Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of C in necrotic fibers. Ann. Neurol. 12:289.
17. Morgan, B. P., C. A. Sewry, K. Siddle, J. P. Luzio, and A. K. Campbell. 1984. Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology 52:181.
18. Tsujihata, M., T. Yoshimura, A. Satoh, I. Kinoshita, H. Matsuo, M. Mori, and S. Nagataki. 1989. Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis. Neurology 39:1359.
19. Nakano, S., and A. G. Engel. 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43:1167.
20. Sewry, C. A., V. Dubowitz, A. Abraha, J. P. Luzio, and A. K. Campbell. 1987. Immunocytochemical localization of complement components C8 and C9 in human diseased muscle. The role of complement in muscle fibre damage. J. Neurol. Sci. 81:141.
21. Hodgetts, J., and B. P. Morgan. 1989. Purification of S protein (vitronectin) by one step immunoaffinity purification procedure. Biochem. Soc. Trans. 18:726.
22. Gasque, P., A. Ischenko, J. Legoedec, C. Mauger, M. T. Schouft, and M. Fontaine. 1993. Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J. Biol. Chem. 268:25068.
23. Gasque, P., N. Julen, A. M. Ischenko, C. Picot, C. Mauger, C. Chauzy, J. Ripoche, and M. Fontaine. 1992. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 149:1381.
24. Rooney, I. A., A. Davies, and B. P. Morgan. 1992. Membrane attack complex (MAC)-mediated damage to spermatozoa: protection of the cells by the presence on their membranes of MAC inhibitory proteins. Immunology 75:499.
25. Kawasaki, E. S. 1990. Amplification of RNA. In PCR Protocols. M. A. Innis, D. H. Gelfand, J. J. sninsky, and T. J. White, eds. Academic Press, Inc., San Diego, CA, pp. 21-27.
26. Engel, A. G., and C. Franzini-Armstrong. 1994. Myology, Basic and Clinical, 2nd Ed., Vol. 2. McGraw-Hill Book Company, New York.
27. Hohlfeld, R., and A. G. Engel. 1994. The immunobiology of muscle. Immunol. Today 15:269.
28. Morgan, B. P. 1989. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem. J. 264:1.
29. Ghebrehiwet, B. 1989. Functions associated with the Clq receptor. Behring Inst. Mitt. 84:204.
30. Lublin, D. M., and J. P. Atkinson. 1989. Decay-accelerating factor: biochemistry, molecular biology, and function. Annu. Rev. Immunol. 7:35.
31. Liszewski, M. K., T. W. Post, and J. P. Atkinson. 1991. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu. Rev. Immunol. 9:431.
32. Kinoshita, T., S. I. Rosenfeld, and V. Nussenzweig. 1987. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocyies. J. Immunol. 138:2994.
33. Lass, J. H., E. I. Walter, T. E. Burris, H. E. Grossniklaus, M. I. Roat, D. L. Skelnik, L. Needham, M. Singer, and M. E. Medof. 1990. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invesl. Ophthalmol. Vis. Sci. 31:1136.
34. Nickells, M. W., J. I. Alvarez, D. M. Lublin, and J. P. Atkinson. 1994. Characterization of DAF-2, a high molecular weight form of decay-accelerating factor (DAF; CD55), as a covalently cross linked dimer of DAF-1. J. Immunol. 152: 676.
35. Gu, D., L. Wogensen, N. A. Calcutt, C. Xia, S. Zhu, J. P. Merlie, H. S. Fox, J. Lindstrom, H. C. Powell, and N. Sarvetnick. 1995. Myesthenia gravis-like syndrome induced by expression of interferon-γ in the neuromuscular junction. J. Exp. Med. 181:547.
36. Ripoche, J., J. A. Mitchell, A. Erdei, C. Madin, B. Moffat, T. Mokoena, S. Gordon, and R. B. Sim. 1988. Interferon-gamma induces synthesis of complement alternative pathway proteins by human endothelial cells in culture. J. Exp. Med. 168:1917.
37. Yoon, S. H., and D. T. Fearon. 1985. Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J. Immunol. 134:3332.
38. Medof, M. E., E. T. Walter, J. L. Rutgers, D. M. Knowles, and V. Nussenzweig. 1987. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J. Exp. Med. 165:848.
39. Rooney, I. A., and B. P. Morgan. 1992. Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76:541.
40. Hara, T., S. Kuriyama, H. Kiyohara, Y. Nagase, Y. Matsumoto, and T. Seya. 1992. Soluble forms of membrane cofactor protein (CD46, MCP) are present in plasma, tears, and seminal fluid in normal subjects. Clin. Exp. Immunol. 89:490.
41. Legoedec, J., P. Gasque, J. F. Jeanne, and M. Fontaine. 1995. Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur. J. Immunol. 25:3460.
42. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990-Soluble human complement receptor type 1: in vitro inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249: 146.
43. Pemberton, M., G. L. Anderson, V. Vetvicka, D. E. Justus, and G. D. Ross. 1993. Microvascular effects of complement blockade with soluble recombinant CR1 on ischemia/reperfusion injury of skeletal muscle. J. Immunol. 150:5104.
44. Piddlesden, S. J., M. K. Storch, M. Hibbs, A. M. Freeman, H. Lassmann, and B. P. Morgan. 1994. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J. Immunol. 152:5477.
45. 2 chimeric complement inhibitor. J. Exp. Med. 174:1451.
46. Halperin, J. A., A. Taratuska, and A. Nicholson-Weller. 1993. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J. Clin. Invest. 91: 1974.